N
Google TrendJONAS BROTHERS (500+) — Jonas Brothers postpone Birmingham concert over weather concerns
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:jonas brothers500+steven kwan500+kings vs warriors200+steffi graf200+boxing200+ben simmons500+lisa500+bill maher500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "CASE: CAR T-Cell Therapy" (30 stories)

Top Headline Story

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
Lead StoryPR Newswirescience
5d ago

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxQY01Ta250WGV3OGQ1aHIyVDd2MjdmRnhTdG9XQkR2TUtpZ2N5LWZLYUtRb3lEV3YtTWoxX1JGZnpKelpNVC1CVi1tOXVHZTZDc1dvemhkV3BLUEFyYk1aM0JtcEcwSjdZWDlVRjRRN3dEZFZQTFk3TC05S0tkWFltZEpYWDJiMk51ZU4zTnhGQ29xRzRrVzNHSGk4Z1FkM19aejFBV1JzaTZweWZ4UkR5NmJHTkFaQS1TRG90QkhfWG9UWVNtRjJCdEp0bHJlMF9iX25HajFUVFhzVFc2NFJFOWN1ODU2Tko4TDF6V1JLZ2o1eEppdEVrSG5CRVg?oc=5" target="_blank">Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+21m ago

jonas brothers

Jonas Brothers postpone Birmingham concert over weather concerns

Filter stories
500+21m ago

steven kwan

Guardians' Steven Kwan Could Shake Up Winter Outfield Market

Filter stories
200+21m ago

kings vs warriors

3 Storylines I'm Focused On in Warriors Preseason Game vs. Kings

Filter stories
200+21m ago

steffi graf

PICTURES: Steffi Graf & Daughter Jaz Feature In Andre Agassi’s ‘Photo Dump’ As Carlos Alcaraz & Karl-Anthony Towns Make Surprise Appearance

Filter stories

Search Results for "CASE: CAR T-Cell Therapy"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients
Penn Medicinegeneral

CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOQkE2NXA4S0pob3FaQVc1Uk1kSDBJSlgwRVBnUzQwTWRNeGxLOXoydnNkaFhUTzdzbklGNTdpaGYtOEVRU2czWjh1c0doQjVxd3NMQ2h1bElUYl9Kallsc3c0WHo4dXZxYkNvanZGSkphLVo3OEFPUW1HdmZKUE9aUFlqR0N3MXVmeWxGMzQ2bHZSX2k2?oc=5" target="_blank">CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients</a>  <font color="#6f6f6f">Penn Medicine</font>

Read Full StoryMore like this
Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series
Natureworld

Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE14WXVCelFmcHNpZEF0RHhBOUdySzU2TXpkUklhMkVFSWJ0RXhlQ19iY0h5aFI1U1pLWGdEajBMWE1NNW1mSVk3VEI3cnpwMjFjMUkzTzJYTTlfem1CbWEw?oc=5" target="_blank">Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
CASE: CAR T-Cell Therapy for Lupus Patient With Kidney Involvement
Cleveland Clinicgeneral

CASE: CAR T-Cell Therapy for Lupus Patient With Kidney Involvement

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOU0RUOHVXNWg5cVZNclVQRTljTTdMc2Z6YVcxQnZiTmc1MFdHanlzNmRDVF92SWEyQk9BUTRJWU1zbFBSc0t5R2JSYTlUOC1Tc21GYjhLUmROcU5XVmZsaEczZVZYeVJyMmozVlpaRzZZY1JZWUVCMGhBdlhkNXQwdHQyVFdHUmFUcXIyc2pqNHE5MzdINjlyTUQ0dTRGR19NcFVxTjVn?oc=5" target="_blank">CASE: CAR T-Cell Therapy for Lupus Patient With Kidney Involvement</a>  <font color="#6f6f6f">Cleveland Clinic</font>

Read Full StoryMore like this
Community Case Forum Explores Advancements and Care Collaboration in CLL
Oncology Nursing Newsworld

Community Case Forum Explores Advancements and Care Collaboration in CLL

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQa3J2eTYtUkVHYkx6VHp0Nmdfb3dvakw4dWROYV9YenI3WFZ5Y3ZaQTByZWg2Mkk0Yi05eWhEWnVwTXVWRlk4cll0bl8tdjlMN1FVSnBIRkhaM21GOXNGdjBDSm9EbWpZOG1ja3pSOW96NFF3TVpsNVA4N0lPdDR4T2VDaHdUT1FaMEViT2ZKRUU0NzRfVVFOU0NZa0hvZHJGUlNzVWE3SDh6MmVK?oc=5" target="_blank">Community Case Forum Explores Advancements and Care Collaboration in CLL</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
Case Report: Durable, well-tolerated complete response to epcoritamab plus pirtobrutinib in Richter transformation relapsing after CD19 CAR T-cell therapy
Frontiersgeneral

Case Report: Durable, well-tolerated complete response to epcoritamab plus pirtobrutinib in Richter transformation relapsing after CD19 CAR T-cell therapy

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQYVJYNjBHNC1CenAwNlQ5bjJ4ZGJpTTNQT3N1RTV0SGxDbHc3d3JuZEY1NFNseEU3MzFUUjI0QU9SWkxjOW1FYXZQXzM1ODF2a240S01IQ2dXeDdmM0dYQ096ZlBoV3pRdHVJUDQ2SGNCcm1rZmt5RmtKM2VXa21XQ1cxZGdIWnJWelRxTTNR?oc=5" target="_blank">Case Report: Durable, well-tolerated complete response to epcoritamab plus pirtobrutinib in Richter transformation relapsing after CD19 CAR T-cell therapy</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
OncLivegeneral

CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPY05WQ1lrUlhIR3J3TXctWmVvUHBMQ21nV2NscDdmRS1tQzRFc0tSRFMwSlhrYWR2V2QzQjhkSXpJdXBzbnVQdVQ1RGtlNUljUm9UdXdLV3Z3MDI0NFNXdFo1eDgyTjBiYkptcUxpem52VWZJLUJxM1hRUXhnajVfZHpMYzFiZ3FFN25VR1BBVVlQSHRXbzZZRFZQWldEdV81a0E?oc=5" target="_blank">CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
CAR T cell therapy leads to 10-year remission for B-cell lymphoma patients
Oncology Centralgeneral

CAR T cell therapy leads to 10-year remission for B-cell lymphoma patients

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNWkhGZllyNDhaNkUzNGZyUWU3NndWdzZJUkdGUWpjMk93ZTMtZ29RN0FiN1lNZU9pX3p4V0Y5VmZzeXF4TWJjaC1YVVBTYVBDcldodjAxMmluTmpfNmNWQ1NOYk1jTVR5ZlZTS2IyTEs0dFJlNlFaOGF4a3NtTGl0ak4tZlJBU0RXWWFLR3pjTFdhQ09ySm1QWXRsX0h4WlhUeUE?oc=5" target="_blank">CAR T cell therapy leads to 10-year remission for B-cell lymphoma patients</a>  <font color="#6f6f6f">Oncology Central</font>

Read Full StoryMore like this
Navigating CAR T Decision-Making in R/R DLBCL
Targeted Oncologygeneral

Navigating CAR T Decision-Making in R/R DLBCL

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPZzdHN1IwRl94UGNDVzAwS0V2UGxQSkQydWVqTXpUdW9DaWNlQkhCb2ZNVUVIMms4d3Q5OGNjMm9kdDNzQ05oWmxySGhyUzU2Z1RCc0VWanRLX1Y5ZFJySFdBUHFPNk5lOUt1bjM2MUFwQnV5VGdBWE4yRTJsUTZhd0JmZHk?oc=5" target="_blank">Navigating CAR T Decision-Making in R/R DLBCL</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma
CancerNetworkgeneral

Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPWFhrdzJBZ0VYdjBlVXRsMXFnY2VUeUV6NHpEVTR1enpHWURIX05RZjgzNGpwX2tCcnp2UEZENjF4YXdoMVlkVEhsZ215b1FmaXRLUEcxUW1Ma3lyMUpNVzF0cy1oMHhXeVBEcmxlNktCYjFoVUZIdFc1b3l6aW8xRVpPWV9xVlZSUTRpTzluckEteXNKUFVaZlFNYkxoSHJwS0VzTFl3bw?oc=5" target="_blank">Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies
Naturegeneral

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFA2dTdqUjBmU0pyNlFGYU9RLXdxc21oNDhfTUJ0WjBIend2ZWRTc0NXVXVSTVJLd09KRXVQREN4eElFQlYxaHUzLVl5UkNfSjUtdmN1Z2NseFFJWGxyVWZV?oc=5" target="_blank">Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy
Cleveland Clinictech

Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcnhuM3BKVEJQZFpJTnIwZUoyZFdQckJ5NzFPenA2TWpnekpEaDUtZHJCcUpxd2ZGOFhqNFJwbzZYOTdlYUlzVHptLXJJb0d3dXpwdkRGV05XdHl2VjhrRnkwT2laTjNrZE5XblU0NS05d1d6LS10WkNyZENELVNqN1ZxZnAycFF0dEhrTUF2UnFGQllfenVrM0k5RzFaWWFmUDZ3NWNLcjVzeS1ZamNxVGFmVlI0YmdLbGRmcHFxdnk?oc=5" target="_blank">Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy</a>  <font color="#6f6f6f">Cleveland Clinic</font>

Read Full StoryMore like this
Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report
Frontiersgeneral

Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNdVpWYjU3ZGRFZnQ1dHdHb00xWlg3c3Z2TlJjQk5zZ3RQM2dNYXh6UmwwRDRocFc2RnAxb2JmU0hOcWIyR3pNcGk4SE1VVzFuVE1tY2hCcTR6T2NKcEZxNzVja19FaXhWdjZUYllwVFplQmpDei1EcExVMFh4aUxvdlZNRkZKejMzMHNDWFVB?oc=5" target="_blank">Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Reflecting on CAR T for First Relapse in Multiple Myeloma
Targeted Oncologygeneral

Reflecting on CAR T for First Relapse in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQdWJTUG5DTHZSbGRCc3BaWFVrRzEtSnFWdDhGeXBaX1VjalZSVmt4cW9GTl83MlZrQnF5V2JQNVBudENBa1BiWUMwUEx5MmtleThMXzlRVDJSZmFSMzI4cF9kdURrLXBhcDV4blZpTng4YlhtOFAtaWNWU1JmcW9HSmRMX2QzeGs4eV9VNGtGdVhBZE5n?oc=5" target="_blank">Reflecting on CAR T for First Relapse in Multiple Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly
Naturegeneral

Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3dXhHeFB5OVl1TndBX3kydWM1VDhUOUQzNjc2NlV3bUhxWURqakYxelhmYS1nZGdpWldOZDFwNVhXRnhRaFhvUmIwT1FPaUVvZldlOWtsOWpDUThqX2Zv?oc=5" target="_blank">Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
TA-TMA occurring after sequential CD7 CAR-T cell therapy and allogeneic hematopoietic stem cell transplantation: a case report
Frontiersgeneral

TA-TMA occurring after sequential CD7 CAR-T cell therapy and allogeneic hematopoietic stem cell transplantation: a case report

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOX28ybUQtNjJqWkxUS0ZySDkzTlZrV2tPZlRZMW5NX1NlTlpwaHRkelFad1hZMFQ5YlBZSFBxMUVaVG1BdlpfSmM5cXV6dW5hbEtTbFAtaTdfN1lkLXF3aGtGb1FZRXU1bXhjRWI5czB2RUN3ZGpKTFVFY3daSGMxTjYzamstakgzbmVsclVGdklQUQ?oc=5" target="_blank">TA-TMA occurring after sequential CD7 CAR-T cell therapy and allogeneic hematopoietic stem cell transplantation: a case report</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
CARTITUDE-4 Data, IMWG Guideline Make the Case for Second-Line CAR T in Myeloma
Targeted Oncologygeneral

CARTITUDE-4 Data, IMWG Guideline Make the Case for Second-Line CAR T in Myeloma

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPc0o3WHRfWHNyZXpZN0FwcTdwN0p0Z0hUTWpkSHFZYzRLWlpzaUdvbVhrU205bnpGZWVFNWJyN2dlWV9IdnJ3U3NpMDRLaWdVU0ZYZ1RGTkRtbkNtaXVUSlJMSmNfT0prTGplbGZ0aG1LNVF2ZGF0ZDh1Z0RENm5NOXhBckpaQXg0WERqVElkdUVILVcxWVQ5Nm5NWnIzeGV5YS1CRzZQalJManF2MTZzRw?oc=5" target="_blank">CARTITUDE-4 Data, IMWG Guideline Make the Case for Second-Line CAR T in Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Case Report: Frontline CD19 CAR-T-cell therapy combined with targeted regimens induces durable complete remission in newly diagnosed secondary CNS lymphoma: a report of two cases
Frontiersgeneral

Case Report: Frontline CD19 CAR-T-cell therapy combined with targeted regimens induces durable complete remission in newly diagnosed secondary CNS lymphoma: a report of two cases

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNekJ5YjkyVnVwVlJ6QmtUNXNhOUtPdEJXdjI5Ymk2SUJVMGx3YWMzcFJ0aUd4OVYyeTVMd1QwLV8xOEpvSWpkX2RfQ0pfZW5Gb3oydER5Tnl5M1g3dHRhT2EyOEs0Y1hCRGY0WDBxcy1Qb21ubUkyRWlGbk9iS052YWJwUW8yQmpJMFBnV0pn?oc=5" target="_blank">Case Report: Frontline CD19 CAR-T-cell therapy combined with targeted regimens induces durable complete remission in newly diagnosed secondary CNS lymphoma: a report of two cases</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Therapy-related myelodysplastic syndrome rapidly evolving to acute myeloid leukemia following CAR-T cell therapy in a patient with refractory diffuse large B-cell lymphoma: a case report
Frontiersgeneral

Therapy-related myelodysplastic syndrome rapidly evolving to acute myeloid leukemia following CAR-T cell therapy in a patient with refractory diffuse large B-cell lymphoma: a case report

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOZTA5dFNTaUFWYTlrakZ5UjRnWnI5b3NySmpKV3M5eUloNXF3cHFpZHBpb0ZseUhsb2Zrd1FIaUE4LWZBckI3TzNZUk1Ea0h3NjF4aWI1VjJaWGp4N1hHbHRDN1VWWGtuWTJCSFJSSlR0YmZDangtd0pDd1Rjb3dXZ1R4Sk1KdzA4WVVsUW53?oc=5" target="_blank">Therapy-related myelodysplastic syndrome rapidly evolving to acute myeloid leukemia following CAR-T cell therapy in a patient with refractory diffuse large B-cell lymphoma: a case report</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Bridging Before CAR T in Myeloma Should Aim For Deep Response, Not Just Stability
Targeted Oncologytech

Bridging Before CAR T in Myeloma Should Aim For Deep Response, Not Just Stability

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPcGdoeUlpSFc0bnV4b2xYZVBnckJvelcwdlpPMEg4WFB1b0p5UnQxMVVYUC05a3hLUlQzWmFPZURQVGVFcHRlSFF3UDlsNlQ1SHh2QVJiY3lSQ1pGMnA4S1dvekFHMUd0aXc3Yms1a0NLNVA0aW9yZUFsek5tT0VxZTlNZVNXeTJmZTNaSS1UWFQ?oc=5" target="_blank">Bridging Before CAR T in Myeloma Should Aim For Deep Response, Not Just Stability</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
CAR T-Cell Therapy Shows Promise in Refractory Myasthenia Gravis, Evidence Still Limited
AJMCgeneral

CAR T-Cell Therapy Shows Promise in Refractory Myasthenia Gravis, Evidence Still Limited

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNTlVQSWZJSWk5T2hOWVcyLXhlM1FVc3R5dDN3UVRxYjk0WDB2ZVNraGZaTDFDOHBwekh2N1JPRUI5cE9HdnVoeC13N0lwTjFncEY3M0NNTW4xTDhlc0dqdGMwQ2pKTTF3T0dsTEJ2WEdXbHl2R3FrcGdpQzc5cHc4NXZ0X0F4RFlYNklDOHNRUHJaX3RXNnFqU2xnM2s3UXJWUDVPQmF4NzNnTVVsU2g1Y2Ntdw?oc=5" target="_blank">CAR T-Cell Therapy Shows Promise in Refractory Myasthenia Gravis, Evidence Still Limited</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Sequencing CAR T-Cell Therapy With Bispecifics in Follicular Lymphoma
CancerNetworkgeneral

Sequencing CAR T-Cell Therapy With Bispecifics in Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQSVpQVjUxd0dHRTZ5QUxwbmJwWURBOHJHbUozMElBU2lHbWVkdWQxQmJDZzRYYVdCd1lOXzVUZ0lZWkRkSzZhbkx4dTdBUUF6OUlISDFQQzUwdmJ2U1ZULXU2SU9MMEdQTGx6dkE2czQ5cDJ4YTN0TGp1MWtsYjZVZUJFZ01Jdng2eHdWY3RzU0x1ajF3LV9kaHpRX2lnZG1HdGlUdTRZNA?oc=5" target="_blank">Sequencing CAR T-Cell Therapy With Bispecifics in Follicular Lymphoma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Sweet-like syndrome secondary to chimeric antigen receptor T-cell therapy for multiple myeloma: a case report
Frontiersgeneral

Sweet-like syndrome secondary to chimeric antigen receptor T-cell therapy for multiple myeloma: a case report

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOWUFhb2VjLXVTZ2IxbDJRYXlQeGVIaG90LUpvd0w4VWtIVTFJM1pJOTFkX2JxREFyMXNud1M0SGx4YndUYVVhd01sQnZZVkY0UUFsZ0VtTnlRTU5ual9wNUFQX3dWbTBRS0JrREtCUXdPbDk1MnhEc0hVVFAzai1qcC0tMFdFVUhGYlllSExsTEtFQQ?oc=5" target="_blank">Sweet-like syndrome secondary to chimeric antigen receptor T-cell therapy for multiple myeloma: a case report</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3
Fierce Biotechgeneral

Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQVTFBZmIwSHVOV1dVb1Z3eWVFOERLOVUwWmowQ3BzdXdwX05hNWcyZTc4UTEwc05oRmNGMGVmZjBmT0JHMDF5b3RiODZIa3R4N09JX01nZXJNSWxEblNqNzllQXRNeWVUbHZUa3lzbGx1aTJaaElVaFFLSTNKZUU0TWxmRU5GUHlIWTZSTGpDakxYdXd0emNkREZVa1VLdG5TRjJiSExWa2JjVVky?oc=5" target="_blank">Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Elucidating CAR T-Cell Candidacy for Diffuse Large B-Cell Lymphomas
CancerNetworkgeneral

Elucidating CAR T-Cell Candidacy for Diffuse Large B-Cell Lymphomas

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNdUgxU2NkOFRwTTFfQzFjY0hlX2d3ZGZseFU1WTNUSTRZV0Q1aGtQc2pWYXNRU2x2eEgxaENCNWYzbUR3NUM4U1REVXpkQnlyaFZsUzRqTl84NzFXbVpvVXFhM2pBaWpuNVF3S2lFSjVkeURaaWlwZ2VYaVJ2ZWFfTExfdmtVSHg0eUpWZVZkdDFYOE1oVVV0M0tBeHFFSUptZEVoUA?oc=5" target="_blank">Elucidating CAR T-Cell Candidacy for Diffuse Large B-Cell Lymphomas</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy
Frontierstech

Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPdVVUU2xGd2tQdVJDT3FnTHlkZWlBZU5QQjJhYXRzQ0xQdERYVEhCUTNWTmlxU2c0cGpyYWQ2Y2xyUXJXZXRoaGJSNGRfcEhXYVpwam0ybWJ4UUk5QkxGcjVia3M4TGxCcnpObTZ6X2ExaHVMQkpBT2ZGZmRfVFk2a3FOU1ctZUJUeHZ0dVlB?oc=5" target="_blank">Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma Responses
CRISPR Medicine Newsgeneral

Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma Responses

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQ1cwUS14bjBWRTNTekh4VnRudWY3bEd3Mk5YT1NaRzJtTjFadWtSbkdrODVQRUxvZFdfM2hwUzF6bkFtYTJSWk42TVlYRVhGZUh0cUozWEN0a3JydFk2bzRxUm5ySmR6ZnJlUG1vVERHWC02emljdTRmRHZPNXdnZlNaNHpkQ05CeEFpLVdoazV6SUVicURYQ3lZRENWbVpJSGk3amNmQ284anc?oc=5" target="_blank">Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma Responses</a>  <font color="#6f6f6f">CRISPR Medicine News</font>

Read Full StoryMore like this
‘Unchartered Territory’: CAR T Results in Ped Rheumatology
Medscapeworld

‘Unchartered Territory’: CAR T Results in Ped Rheumatology

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOV3pPblJIM2RrMzY2bktCQ3lxelo0bEhOQWhSTGR1NWZiOEhHS2lQdExSeUhraFlhTXJ3NG1oY1hYSm50aE5XYTk5VFZXWTdoU0FmZ0lhMzhIRFo0cnFnd25QQVZFemxwLUtBeGxHYXB2V25mZWUtaGRCdHZFQUFGblFzNEhud1ZNWWl5SkxObHFmdlZCSVBFTmNsaG1DdndhMXVRbzJ4OUE?oc=5" target="_blank">‘Unchartered Territory’: CAR T Results in Ped Rheumatology</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Cell Therapy Trials Report More Data on Remissions, Relapses in Severe Refractory Autoimmune Diseases
Medscapeworld

Cell Therapy Trials Report More Data on Remissions, Relapses in Severe Refractory Autoimmune Diseases

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQempLbzJfclZ0VDB3V05VUXN6VjFXdENvRVFEU3R0NndjZnRRQ3R3ekZQSGVsY1BoSWpHYmV6cktXZnZRc2dLTEpVMzlwend2WWtsNlF5WU1tNktack80QVU4NFBVMnpOLVhjRzBjTkFaRER3SnlaNnJiWXBiSFRpVjZESm92d1Jzd3RaMTY1TWo5bFlDTUpnZnd1RHFzc3lyZVRpSmoyTGVIdw?oc=5" target="_blank">Cell Therapy Trials Report More Data on Remissions, Relapses in Severe Refractory Autoimmune Diseases</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma
Targeted Oncologygeneral

New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPdEozS0VQeWQtcC0ybE9BWElQbndNWXpVamZ0dXpQdnNSSjI1cElSbzh4UGFuaXNaMU1XMmktZnF2YmQ4Nk5WYVZ6ZE5VOUFuci12NWxuaWllYVFuN2hmaXAyUHFGTnZYS2M5SUh4LUtLdkxqSk0yd2x5aGdhRkNwb0lic1hLYUlmVUpWa3JsdFVheWNzN1BDX0w3OV9UYjdWNWRMcUloM255YjVYN2R5Z2VR?oc=5" target="_blank">New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
"CASE: CAR T-Cell Therapy" — Live Google News Trends & Headlines